Apr 14, 2017

More than 15 million Americans have coronary heart disease and most should be taking aspirin daily.1  Given aspirin’s ubiquity in cardiovascular medicine and patients’ pill boxes, it is shocking that there are still so many unanswered questions about aspirin use.  Which dose and dosage forms should be prescribed?  How common is aspirin resistance?  What is the relationship between platelet inhibition and clinical outcomes?


Comments: 0
Mar 24, 2017

Many patients with atrial fibrillation (AF) received triple antithrombotic therapy after undergoing a percutaneous coronary intervention (PCI) and receiving cardiac stent. Triple therapy consists of warfarin plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and low-dose aspirin. But is triple therapy the best approach? This practice, while widely employed, is not entirely evidence-based.

Comments: 0
May 16, 2016

Patients who've had an ischemic stroke or transient ischemic attack (TIA) are at very high risk for recurrent vascular events. The current standard of care is to address cardiovascular risk factors. The Insulin Resistance Intervention after Stroke (IRIS) trial examined the benefits and risks of pioglitazone use after a recent ischemic stroke or TIA.

Comments: 0
Oct 30, 2015

After a patient has a transient ischemic attack (TIA) or minor stroke, the risk of having another is alarmingly high — 10% to 20% will have another stroke within 3 months and most events occur within 2 days.1-3  Both the American Heart Association (AHA) and American College of Chest Physicians (ACCP) guidelines recommend aspirin 160-325mg within the first 48 hours of symptom onset.4-5  The CHANCE (Clopidogrel in High risk patients with Acute Non-disabling Cerebrovascular

Comments: 0
Jul 24, 2015

Stroke is responsible for 1 in 19 deaths in the United States each year and is the leading cause of long-term disability — arguable an outcome worse than death.1 More than 36 billion was spent on stroke treatment and rehabilitation in 2010.  Many strategies are used for the secondary prevention of stroke, but the real impact on health and healthcare cost can only be achieve by preventing the first stroke.

Comments: 0
May 10, 2011

For patients with atrial fibrillation, what’s the best scoring system to estimate stroke risk? Clinicians have long relied on the CHADS2 [congestive heart failure, hypertension, age ≥ 75 years, diabetes, and previous stroke or TIA] scoring system to make antithrombotic treatment decisions.

Comments: 2
Nov 4, 2010

Clinicians and patients alike have been anxiously waiting for an oral alternative to warfarin. That wait appears to be finally over. On October 19, 2010 dabigatran (Pradaxa®) was approved by the FDA and became the first oral direct thrombin inhibitor available in the United States. Unlike its predecessor ximelagatran, dabigatran doesn’t seem to cause liver toxicity.

Comments: 8